生物活性

• 描述Vidofludimus (Vido) is a novel oral immunomodulatory drug that inhibits dihydro-orotate dehydrogenase and lymphocyte proliferation in vitro. Ex vivo Vido completely blocked IL-23 + IL-1β-stimulated secretion of IL-17 by colonic strips. In vivo Vido treatment alone most effectively reduced macroscopic and histological pathology and the numbers of CD3+ T cells^[3]. Vidofludimus is 2.6 times more potent in inhibiting DHO oxidation by human DHODH (dihydroorotate dehydrogenase) compared to teriflunomide. The potency or vidofludimus to inhibit rat or mouse DHODH is 7.5 and 64.4 time lower than the for the human DHODH, respectively^[4]. Moreover, vidofludimus also possesses remarkable beneficial effects in reducing NAFLD (Non-alcoholic fatty liver disease) by targeting FXR(farnesoid X receptor) ^[5].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT00820365	Inflammatory Bowel Disease (IB... more >>D) Collapse <<	Phase 2	Completed	-	Bulgaria ... more >> Tokuda Hospital Gastroenterology Division Internal Medicine Department Sofia, Bulgaria, 1407 UMHAT "Sv. Ivan Rilski" Gastroenterology Clinic Sofia, Bulgaria, 1431 UMHAT "Tsaritsa Ioanna" - ISUL Gastroenterology Clinic Sofia, Bulgaria, 1527 Germany Charité, Universitätsmedizin Berlin, Campus Virchow-Klinikum Berlin, Germany Klinikum der Ruhr-Universität Bochum, St. Josef-Hospital, I. Medizinische Klinik Bochum, Germany Universitätsklinikum Freiburg, Gastroenterologie, Hepatologie, Endokrinologie und Klinische Infektiologie Freiburg, Germany Schwerpunktpraxis für chronisch entzündliche Darmerkrankungen Hamburg, Germany Gastroenterologische Gemeinschaftspraxis Herne Herne, Germany Universitätsklinikum Schleswig-Holstein Campus Lübeck Lübeck, Germany Technische Universität München II. Medizinische Klinik des Klinikums rechts der Isar München, Germany Gastroenterologische Gemeinschaftspraxis am Germania-Campus Münster, Germany Universitätsklinikum Regensburg Klinik und Poliklinik für Innere Medizin I Regensburg, Germany Robert-Bosch-Krankenhaus Stuttgart Stuttgart, Germany, 70376 Romania Elias University Emergency Hospital Bucuresti, Romania, 011461 Colentina Clinical Hospital Bucuresti, Romania, 020125 University Emergency Hospital Bucuresti, Romania, 050098 Collapse <<
  NCT01010581	Rheumatoid Arthritis	Phase 2	Completed	-	Bulgaria ... more >> MHAT "Kaspela" Department of Rheumatology Plovdiv, Bulgaria Diagnostic Consulting Centre "Sv. Anna" Sofia, Bulgaria Military Medical Academy Sofia, Bulgaria National Multiprofile Transport Hospital "Tsar Boris III" Internal Clinic Sofia, Bulgaria UMHAT "Sveti Ivan Rilski" Sofia, Bulgaria Czech Republic Rheumatology Outpatient Clinic Hlučín, Czech Republic Diagnostic Center Mediscan Praha 11, Czech Republic Institute of Rheumatology Praha, Czech Republic Poland Centrum Miriada, Prywatny Gabinet Specjalistyczny Białystok, Poland Mazowieckie Centrum Badań Klinicznych s.c. Grodzisk Mazowiecki, Poland Śląskie Centrum Osteoporozy Katowice, Poland Specjalistyczny Ośrodek ALL-MED Kraków, Poland NZOZ Reumed Lublin, Poland Prof. Dr Hab. n. m. Leszek Szczepański Lublin, Poland Poznański Ośrodek Medyczny NOVAMED Poznań, Poland Wojewódzki Szpital Reumatologiczny Sopot, Poland NZOZ "Nasz Lekarz" Toruń, Poland Centrum Leczenia Chorób Cywilizacyjnych Sp. z o. o. S. K. A. Warszawa, Poland Centrum Medyczne Osteomed NZOZ Lecznica Specjalistów Warszawa, Poland NZOZ Materia Medica Wrocław, Poland Romania Clinic Hospital Sf. Maria Bucharest, Romania Emergency Hospital "Prof. Dr. Gerota" Bucharest, Romania SC Duomedical Bucharest, Romania SC Ianuli Med Consult Bucharest, Romania County Hospital Cluj - Rheumatology clinic Cluj Napoca, Romania Clinical County Hospital of Targoviste Targoviste, Dambovita, Romania Private Practice Prof. Dr. Mioara Banciu Timisoara, Romania Collapse <<
  NCT03722576	Primary Sclerosing Cholangitis	Phase 2	Not yet recruiting	November 2020	United States, Arizona ... more >> Keith D. Lindor, MD Not yet recruiting Phoenix, Arizona, United States, 85004 Contact: Elizabeth Carey, MD    480-515-6296    carey.elizabeth@mayo.edu    Contact: Nicholas F LaRusso    507-284-1006    larusso.nicholas@mayo.edu Collapse <<

• 更多
• 参考文献

• [1] Fitzpatrick LR, Small JS, et al. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J Pharmacol Exp Ther. 2012 Sep;342(3):850-60.

  [2] Kulkarni OP, Sayyed SG, et al. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice. Am J Pathol. 2010 Jun;176(6):2840-7.

  [3] Fitzpatrick LR, Small JS, Doblhofer R, Ammendola A. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J Pharmacol Exp Ther. 2012 Sep;342(3):850-60

  [4] Muehler A, Peelen E, Kohlhof H, Gröppel M, Vitt D. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020 Aug;43:102129

  [5] Zhu Y, Xu S, Lu Y, Wei Y, Yao B, Guo F, Zheng X, Wang Y, He Y, Jin L, Li Y. Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD. Front Pharmacol. 2020 May 14;11:590

• 更多

• Collapse